16 July 2026 in European Journal of Vascular and Endovascular Surgery
Popliteal artery aneurysms represent the most common peripheral arterial aneurysm. The optimal treatment strategy for popliteal artery aneurysms remains controversial. This study aimed to systematically evaluate and compare the clinical outcomes of endovascular versus open surgical repair of popliteal artery aneurysms. MEDLINE, EMBASE REVIEW METHODS: A systematic review and meta-analysis were conducted following the PRISMA guidelines (PROSPERO registration number CRD420251011632). Risk of bias was assessed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias tool, and evidence certainty was evaluated using the GRADE approach. Primary outcomes included primary and secondary patency rates and freedom from reintervention. Nineteen studies, including 13 473 limbs (2 989 endovascular, 10 484 open), met the eligibility criteria. Open repair was associated with higher primary patency (HR 1.92, 95% CI 1.26 - 2.94, p = .003) and secondary patency (HR 1.60, 95% CI 1.04 - 2.44, p = .030) compared with endovascular repair. Freedom from reintervention also favoured open repair (HR 1.84, 95% CI 1.26 - 2.67, p = .001), whereas overall survival, freedom from amputation, and 30 day/in hospital mortality did not differ significantly between techniques. Endovascular repair resulted in a shorter hospital stay (mean difference -3.25, 95% CI -4.05 - 2.45, p < .001). Subgroup analyses showed that autologous vein bypass had superior primary patency versus endovascular repair (HR 2.37, 95% CI 1.45 - 3.88; p < .001), whereas prosthetic grafts did not differ significantly (HR 1.28, 95% CI 0.76 - 2.15; p = .35). The overall certainty of evidence for the primary outcomes was rated very low. Open surgical repair of popliteal artery aneurysms offers superior primary and secondary patency and should be the preferred treatment option in patients with acceptable operative risk. Endovascular repair may offer an alternative with a shorter hospital stay but carries a higher rate of reintervention.
15 March 2026 in British Journal of Clinical Pharmacology
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx prescribing recommendation (CPIC Levels A or provisional A/B) were reviewed, using keyword searches to identify relevant content and estimating the reading age of PGx information in PILs using the Flesch–Kincaid grade level. Among 353 products, 281 (80%) SmPCs contained PGx information, but this was reflected in only 115 (33%) PILs. Where present, the PGx content in PILs required an average reading age of 19.1 years, far exceeding the typical UK reading age of 9–11 years. As the availability of genomic data becomes increasingly routine, the variable PGx information provided in PILs risks undermining patient understanding, engagement and safe personalized prescribing.